About Opthalmology Drugs
Opthalmology drug is used to treat eye infections. The increasing number of patients with eye disorders and growing geriatric population driving the demand for Opthalmology drugs. For instance, according to the report published by the Food and Drug Administration in 2018, globally over 1.3 billion people are affected by a different type of vision impairment. The majority of patients with vision impairment are over the age of 50 years. Further, technological advancement in the healthcare industry and increasing healthcare infratstrure in the developing economies expected to drive the demand for ophthalmology drugs over the forecasted period.
Attributes | Details |
---|
Study Period | 2018-2028 |
Base Year | 2022 |
High Growth Market | North America |
Unit | Value (USD Million) |
CAGR | 6.31% |
Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Opthalmology Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Abbott Medical Optics, Inc. (United States), Carl-Zeiss AG (Germany), Ellex Medical Lasers Ltd. (Australia), Essilor International S.A. (France), Sun Pharma (India), Topcon Corporation (Japan), Novartis AG (Switzerland), Bausch & Lomb, Inc. (United States), ALLERGAN PLC (Ireland), Pfizer, Inc. (United States) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Insight Vision Inc. (United States), Nidek Co.Ltd (Japan), Regeneron Pharmaceuticals, Inc. (United States) and Santen Pharmaceutical (Japan).
Segmentation Overview
AMA Research has segmented the market of Global Opthalmology Drugs market by Type (Prescription Drugs and Over-the-Counter Drugs), Application (Maintenance and Servicing and User Acceptance and Adaptation) and Region.
On the basis of application, Anti-Glaucoma segment is dominating the market in the year 2022On the basis of geography, the market of Opthalmology Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Spain, Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Indication, the sub-segment i.e. Dry Eye will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Biologics will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic Class, the sub-segment i.e. Anti-Glaucoma will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage Form, the sub-segment i.e. Liquid Ophthalmic Drug Forms will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Development of Combination Therapies for Treating Ophthalmic Disorders and Technological Advancement in the Healthcare Industry
Market Growth Drivers:
Increasing Prevalence of Eye Disorders and Growing Geriatric Population
Challenges:
Lack of Awareness in the Emerging Economies
Restraints:
Stringent Government Regulations Regarding Drugs and Threat of Side Effects Associated With Ophthalmic Drugs
Opportunities:
Increasing Demand of Ophthalmic Drugs for Treatment of Retinal Disorders and Growing Healthcare Infratstrure in the Developing Economies
Market Leaders and their expansionary development strategies
In Dec. 2023 Carl Zeiss Meditec AG announced today that it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Center (International) B.V. (D.O.R.C.) from the investment firm Eurazeo SE, Paris, France.
In December 2023,Carl Zeiss Meditec AG announced today that it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Center (International) B.V. (D.O.R.C.) from the investment firm Eurazeo SE, Paris, France. The acquisition will enhance and complement ZEISS Medical Technology’s broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, including retinal disorders, cataracts, glaucoma and refractive errors.
“The Food and Drug Administration (FDA), a regulatory agency within the Department of Health and Human Services, regulates the safety and effectiveness of drugs sold in the United States. FDA divides that responsibility into two phases. In the preapproval (premarket) phase, FDA reviews manufacturers’ applications to market drugs in the United States; a drug may not be sold unless it has FDA approval. Once a drug is on the market, FDA continues its oversight of drug safety and effectiveness. That postapproval (postmarket) phase lasts as long as the drug is on the market.”
Key Target Audience
Opthalmology Drugs Manufacturers, Traders and Distributors of Opthalmology Drugs, Research and Development Institutes, Potential Investors, Nationalized Laboratory, Government and Research Organizations, Trade Associations and Industry Bodies, Commercial Research & Development Institutions and Others
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.